Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo offers hope for aggressive lymphoma in diverse patients

NCT ID NCT04981795

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic minority patients. Researchers measured side effects, tumor shrinkage, and how long patients lived without the cancer getting worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

102 people

The number who actually took part.

Started

Sep 2021

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Community Study- 40 sites across the USA

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Criteria: Inclusion Criteria: 1. Age ≥18 years at the time of diagnosis of R/R DLBCL 2. Initiated or initiating tafasitamab treatment 3. R/R DLBCL patients who have received at least one (1) prior line of treatment for DLBCL 4. Histologically confirmed DLBCL such as: a) DLBCL not otherwise specified (NOS) b) T-cell histiocyte-rich large B-cell lymphoma (THRLBCL) c) Epstein-Barr virus (EBV)-positive DLBCL of the elderly d) Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse, according to Revised European American Lymphoma (REAL)/World Health Organization (WHO) classification e) Patients with evidence of histological transformation to DLBCL from an earlier diagnosis of low-grade lymphoma (i.e., an indolent pathology such as follicular lymphoma \[FL\], marginal zone lymphoma \[MZL\], chronic lymphocytic leukemia \[CLL\]) with a subsequent DLBCL relapse f) High-grade B-cell lymphoma: i) DLBCL with MYC and BCL2 or BCL6 translocation (double-hit) and MYC and BCL2 and BCL6 translocations (triple-hit) ii) High-grade B-cell lymphoma, NOS 5. Signed and dated ICF by the patient or the patient's Legally Acceptable Representative (LAR), for patients with prospective data collection, as applicable. For deceased or otherwise unreachable patients, no informed consent will be obtained for data collection in the study, provided that the competent Independent Ethics Committee (IEC)/Institutional Review Board (IRB) has provided favorable opinion and that any other local regulatory requirements on this matter are met Exclusion Criteria: • Initiated or initiating tafasitamab treatment in the context of an interventional study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B-cell lymphoma

Contacts and locations

Locations

  • Alabama Oncology

    Birmingham, Alabama, 35211, United States

  • American Oncology Partners of Maryland PA

    Bethesda, Maryland, 20817, United States

  • Clearview Cancer Institute

    Huntsville, Alabama, 35805, United States

  • Duke University

    Durham, North Carolina, 27705, United States

  • Froedtert & Medical College Clinics

    Milwaukee, Wisconsin, 53226, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Integris Cancer Institute of Oklahoma

    Oklahoma City, Oklahoma, 73142, United States

  • Lankenau Medical Center

    Wynnewood, Pennsylvania, 19096, United States

  • Leo Jenkins Cancer Center/ECU School of Medicine

    Greenville, North Carolina, 27858, United States

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • McFarland Clinic P.C.

    Ames, Iowa, 50010, United States

  • Mercy Medical Center

    Canton, Ohio, 44708, United States

  • Mission Cancer and Blood

    Des Moines, Iowa, 50309, United States

  • Morristown Medical Center

    Morristown, New Jersey, 07960-6136, United States

  • Ohio Health Marion Area Physicians

    Marion, Ohio, 43302, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903-2681, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • Tri County Hematology & Oncology Associates, Inc

    Massillon, Ohio, 44646, United States

  • Tulane Cancer Center

    New Orleans, Louisiana, 70112, United States

  • UW Medicine

    Seattle, Washington, 98109, United States

  • University of California, Irvine Medical Center

    Orange, California, 92868, United States

  • University of Michigan Comprehensive Cancer Center Michigan Medicine

    Ann Arbor, Michigan, 48109, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • VA Medical Center - Durham

    Durham, North Carolina, 27705, United States

  • Westchester Medical Center

    Hawthorne, New York, 10532, United States

  • Yakima Valley Memorial Hospital/North Star Lodge

    Yakima, Washington, 98902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.